# Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

> **NCT03531905** · PHASE2 · COMPLETED · sponsor: **Esperion Therapeutics, Inc.** · enrollment: 242 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Cholesterolemia

## Interventions

- **DRUG:** Bempedoic acid + Ezetimibe FDC Oral Tablet
- **DRUG:** Ezetimibe 10 mg Oral Tablet
- **DRUG:** Placebo Oral Tablet
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03531905
- **Lead sponsor:** Esperion Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2019-06-18
- **Final completion:** 2019-06-18
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531905, "Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03531905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*